Member Info for SocialistB

@ JerrySpaniel, thanks for your pretty sure confirmation that the loan agreement might be related to the Juri JV.

I do not mind a JV in Juri,

But I do mind the giving up 70% for peanuts from the outset and not a single penny going into GGP’s coffer to help the company stay afloat while we are not cash generative.

In my view it is not the right way to treat a business partner.

I am fine with the concept of: I’ll scratch your back if you scratch my back.

By that concept, I mean: 10% of Juri for providing a loan facility at 8% when no one else was willing to lend us any money and then the possibility for Newcrest to earn in further percentages in the future and a right of first refusal.

I am not going to diss GH and the BOD for the deals they made as I fear that not even SD could have gotten a better deal under the circumstances.

I say that because, I really fear that we were bullied by Newcrest into accepting conditions that should be unheard of in a JV.

I agree with your assessment of all the times that Newcrest could potentially have twisted our arm and made demands that was highly unfavorable to us.

And that is why, if that is the case, I do not think we should enter into any more JV’s with Newcrest.

Because if that is the way they treat a business partner, you really got to be a masochist to ask for more of the same treatment.

It is all assumption and guess work how and why the different deals got struck, but for me the proof is in the pudding, namely the way Newcrest goes out of the way to argue for a low-ball offer for the 5% option.

They could and should in my view have come up with the number SD and team came up with, in fact it should have been even higher.

If that had been the case, I would have been in doubt about my recent expressed assumptions, but as it stands, I am not.

You’re right it is better to look forward to a time with SD at the helm and the prospect that he can replicate the trajectory for GGP, that he created as part of a team at Northern Star.

And he has clearly expressed how important a catalyst Havieron is, to get the ball rolling in that direction.

Like you, I have also been to the hustings at America Square, and I too am impressed by SD, but if Newcrest keep playing the way I fear they have been up till this point then I am afraid we are still gonna face unwanted behavior in the future.

We are already lined up for 2 JV’s where I fear we can see more of this behavior. I do really not think we should willingly line ourselves up a third time.
No, let’s have a professional courteous relationship at Havieron and Juri, but let’s try to go alone on the rest of our other tenements or find another company to JV with.

Having said that, if @Taverham is correct in his 07:13 post about Australian business culture then it could very well be worth to stick to the devil you know.

But I am not a fan of the idea.

Part 2.

But if my assumptions in the last 2 posts are more correct then wrong, then based on the experience dealing with Newcrest up to now, I do not like the Idea of JV'ing another single ounce of gold to them from our other tenements.

I know SD has mentioned the possibility to renegotiate the percentage deal on Havieron and Juri if we strike gold at Scallywag and does a JV with Newcrest on this tenement as well, but I feel I have been to to burnt by them with the report that Newcrest produced to justify their offer for the 5% at Havieron.

I would want to see amends from Newcrest, before reconsidering my stance.

The best amend I can think of, is declining the 5% option, because that is an absolute fortune in future income it will be handing to GGP.

So the question that remains is: Can a leopard change it's spots?

Part 1.

I do not have any intention of slamming GH with the post that I wrote earlier.

I am sure that he and the BOD did the best that they could during the negotiations of the Juri deal.

I am just sad that if my assumptions are more correct then wrong about demands from Newcrest, that our JV partner have used their position of power to get one over us at GGP.

And no, do not come and tell me that is how it has to be in business, because it is not.

Years and years ago, I had the pleasure of working for a guy who had started a company from scratch and done all the hard manual work himself. Many decades later, and with several hundred employees and operations in several countries and the son's and various professionals having taken over the day to day running of the business, the opinion was still that the company had only done a good deal if both parties was happy with the deal.

I think, that is a good motto to live by while doing business.

But as the saying goes: "A Leopard cannot change it's spots" and that is why I after Newcrest's attempt to justify a lowball offer for 5% extra at Havieron with a first class well writen report are more scared of them then ever before.

SD have a point when he say's it a bad idea to have a win loose scenario written into a contract.
From my point of view, I can see why originally a cut of deal has been accepted or proposed, assuming it has had something to do with not risking that the funds a 5% sale of Havieron would raise, could be kicked into the long grass.

To be fair to Newcrest, they have without a doubt spent a lot of money at Havieron so far.

But those expenses are on exploration and justification to go mining.

I do not remmeber that they have actually paid as much as a dime to GGP.

TO BE, OR NOT TO BE. THAT IS THE QUESTION.

Buying or not buying the 5% option, that Newcrest have a contractual right too, is a perfect chance for Newcrest to show that they appreciate that GGP choose them as a JV partner, by offering a decent sum for the 5%. The first sum of money from Newcrest and directly down into the coffer of GGP. Or by deciding not to take up their contractual right they can show the same respect.

In my view it is unlikely that they will not take up the option. And they have truly shown their spots with the report that they used to argument for their lowball offer.

I am therefor fearful that Newcrest will also in the future try to behave in an undesirable way towards GGP, given they get the chance to do so.

But I do think that it will be more difficult in the future with SD on board and our knowledge of how Newcrest operates.

Personally it is my opinion that we have 2 JV's with Newcrest and we should leave it at that.

I am glad that SD and SB get on well and equally so the geological teams.

And please keep that going for our 2 current JV's.

A lot of what is to follow will be with the caveat: " if memory serves me right"

I have never understood the motivation for entering into the Juri deal and I do not feel that we have been given a proper explanation as to why such a poor deal was accepted.

After having experienced Newcrest produce a report, a couple of hundred pages long and from what I have heard very well versed and with solid arguments for what they wanted to pay for 5% extra of Havieron, should they decide to take up that option, I am scared of that company.

Having heard that the GGP team managed to 5 double the sum, I have to assume that the offer from Newcrest for 5% of Havieron was in the region of 12 million. This is an assumption as I have no knowledge of what Newcrest offered. But this assumption makes me even more scared of Newcrest.

So, I cannot help but wonder if Newcrest twisted GGP's arm when they made the loan facility and demanded a chunk of Scallywag, but instead ended up settling with a gigantic piece of Juri instead. GH seemed so pleased when he announced that we kept all of Scallywag.

If that is the case, then we are in a situation where our JV partner acts like a bully in my view.

I hope I am wrong, but I fear I am not.

From where I stand, GGP got nothing out of the Juri deal. Nothing worth to talk about, from what I gather in the RNS's released at that time.

Newcrest paid us nothing.

Yes, they have to spend money on exploration, but had it been their own piece of land, then that would also have been the case, so why did GGP not get some money for letting Newcrest in on the action in Juri?

A mutually good deal between JV partners on another tenement and project (Havieron) could among other options have looked like this:
Newcrest would have gained 10% of Juri for 2 million paid directly to GGP with no demands attached other then keeping the license going. And then Newcrest would have the right to buy further instalments at various higher prices up to a maximum of 30-40% of Juri. Should GGP decide to sell their share of Juri, Newcrest would have a right of first refusal.

If it had been announced that Newcrest had agreed to give a loan to GGP at 8% to finance their share of Havieron and in return the deal above had been agreed, then I would have been more then happy and found it to be a symbiotic relationship between 2 JV partners.

But it was not that kind of a deal that was made with Juri.

I am therefor still to this day disappointed that we did not retain it 100%, because in less then 2 years we are likely to be cash generative, and then we could have spend all the money we wanted to throw at it.

How can Newcrest improve my impression of them as a company?

Not take up the 5% option at Havieron.

And simply state that they do not do so, because they value the JV with GGP and despite it is ENTIRELY in their right to excersize the option, they find it unfair to do so, because Havieron is expected to become so big.

From today's RNS.

The Company's state-of-the-art research facility includes approximately 10,000 rentable square feet of purpose-built lab space including two clean rooms for cell therapy manufacturing. In addition to continuing and expanding its research, Hemogenyx Pharmaceuticals is now able to manufacture cells in-house, accelerating and simplifying the commercialisation of its major cell therapy product candidates. The Company will first use its clean rooms to produce its HEMO-CAR-T cell therapy for the treatment of acute myeloid leukemia.

This is just the first piece of good news that I expect to receive over the next 6 months or so.

Nice work @ JustHereForHemo

I am sure we are many who appreciate the work you have put into this "poster"

Please keep up the good work.

(However, your stinger car example is still the gold standard to me:-)

@JustHereForHemo.

I cannot believe (actually, I can) that I forgot about that RNS

I did go over it a couple of times when it came out.

I better ask Mr. Sandler to develop a bait module, to capture the proteins or whatever, that causes people to get a bad memory:-)

Joke aside, the potential of it being effective against bacterial infections is seismic in my book.
Antibiotics can cause a bacteria to become resistant over time.
Some already are.

If this could solve that problem.

Vow

@JustHereForHemo

I have missed the claim to ALMOST ANY bacteria/cells

I am aware of the almost any virus claim (which is downright impressive)

Can you please provide a link to where Mr. Sandler has mentioned CBR could potentially work on bacteria as well.

Many thanks in advance

When is the best tactical time to release news that we are going clinical?

A: This week?

B: Next week, while Mr. Sandler is in London?

C: After Mr. Sandler has left London?

There is no doubt in my mind that the announcement will be (or at least SHOULD be) pivotal to the share price, but when will the announcement have the biggest positive psychological BOOM effect.

I am on the fence in regard to the 2 following thought experiments:

1. When Mr. Sandler gives a speech in London 23-25 May 2022 he refers to a RNS from the previous week (today, tomorrow) where it has been announced that they will become clinical as per ???? date.

2. To a live audience of peers and investors Mr. Sandler say's : I am honoured to announce to you as some of the first to know, that Hemogenyx will become clinical per ???? date.
Now that would be a bombshell, except I assume it would have to be released in a RNS first.

What is your thoughts?

@Hulver.

Thank you for providing the links and information.

I really appreciate it.

It is impossible for me to buy shares with my provider at these lovely low prices.
I have tried 3 times over the last 30 minutes or so, and for the low sum of 500 pounds.
It just keeps going to NEGOTIATED ORDER.

Could this be a good sign about what's to come?

Or is it a sign that the share is being manipulated if we do not see a sustained rise in the share ?

(If Mr. India is going to give it a rest, wondering why the share price is not moving/people are selling at these low price, someone has to take up the baton:-)

@Hulver.
I have either missed something here or is likely not to have access to the various social media sites.

Can I please convince you to provide a link to any open sites or copy and paste from more restrictive sites, holding the information you are referring to.

Hopefully, others then me will appreciate your efforts.

I too (maybe I am not speaking for the above posters) but I most definitely think the bashing of Mr. Sandler that has taken place this week has been unjustified.

I find that he was between a rock and a hard place, that he was doomed no matter what.

Well, unless the share price had a significant rise, I assume.

Last week it was well documented on this board that HEMOGENYX had in previous years been a last minute boy, when it came to the annual financial statement, and true to form they did not disappoint in this regard, this time around either.

I was happy, that it was not released during trading hours last Friday. It gave me time to read the announcement properly.
And to pass on the good news about being well funded, to start clinical trial, to a friend and an investment company.

A thing I would have been hesitant to do, without the knowledge about HEMOGENYX's cash balance.

So, I am now glad, that those entities have a chance to get in at this low price, should they desire to do so.
For me, it is another week closer to a potential windfall that I would like to invest here in Hemogenyx.

And I would love it to be at this price level.
So, from a purely selfish point of view, I'll be happy to see the share price remain at this level for the next 3 months.

Is this the reason that I am willing to defend Mr. Sandler, maybe partly unsubconsiosly, who knows. But I would like think it is more because I actually like the way he acts or the reason why he acts as he does.

This is me assuming his reasons are as follows: preserve cash, dedicate EVERY SINGLE penny to research (and some to the team). Let the science do the talking, I find it refreshing that I have a CEO who is not out there pumping the share price, if just all CEO's where honest like that, I would have saved some money on companies that I took a gamble on and lost on.

My take on why the share price is not moving, has not really changed.
The market appetite is just not there at the moment, not for the state we're currently in. (Despite it being a fantastic state)

So when will it change?

1. When we become clinical?
2. When we have a positive feedback on a phase 1 trial?
3. When a JV or collaboration is announced?
4. When a lump-sum and profit sharing is agreed?
5. When HEMOGENYX becomes cash generative?
6. When dividends starts to be paid?

If point 2 does not happen, then forget about point 3-6.

If and it is a big IF the market has not reacted positively by point 6, then it must mean that the market is either broken or does not know what we are sitting on.

Then we can only sit back and enjoy the dividends.
Not the worst position to be in, when a share trades in less then 2 pence:-))

@Hydrogen

I'd so wish I could give you double points for your 0805 post today.

Very well written, keep up the good work please.

PART 2

Maybe our best shot is the Gates foundation as they make it clear they also work with the private industry.

“We work with an array of partners, including government agencies, donors, multilateral organizations, nongovernmental organizations, academic institutions, community organizations, and private industry. We also work to ensure that adequate funding and appropriate policies are in place to support HIV prevention and treatment efforts, research and development, and efforts to understand the needs of high-risk populations.”

https://www.gatesfoundation.org/our-work/programs/global-health/hiv

And I think the Gates foundation would also be an excellent partner for a cure against Ebola

Or the European Union.

https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/ebola_en

My favourite though, as I am an avid goer to the museum here in London, is the Wellcome trust.

They have already made donation to research:

“In December 2016, trials of an Ebola vaccine showed it provided a high level of protection against a strain of the deadly disease. The vaccine, made by Merck, Sharpe & Dohme, was funded by Wellcome, DFID and the Norwegian Government among others, and has been proved safe for human use.”

https://wellcome.org/news/wellcome-pledges-new-funds-tackle-ebola-outbreak

For good measure, here is the link to their Grant funding page:
https://wellcome.org/grant-funding

Count down for trades today has begun.

I am excited to see, where we end up tomorrow.

GLA, but not least to all those potential patients Hemogenyx can help in the future, should our products be successful (and of course they will be)

PART 1

@JustHereForHemo.

I agree, knowing that funding is in place will give us all piece of mind.

And I believe that to be the case.

Mr. Sandler have shown in the past, that he can be frugal, but I admit there might have been many big expenditures as of late. How big, we will find out tomorrow.

When Mr. Sandler was asked if he regretted the CLN debacle, he said NO, because otherwise they would not have been able to get the money that they got. (And thereby the opportunities that it unlocks)

I seem to remember that was a hard statement for many to swallow. It was deemed to be arrogant.

But if the funds that was raised have made it possible to move the Lab to new premises, get the equipment needed for one or more of our projects and allows us to go through phase I of clinical trials (and hopefully get proof of concept) then I think many will eat their words.

I for one am extremely happy, that we have had the dip we have had.

No, it is not fun sitting with over 50% loss, but what is fun and great, is that it has allowed me to build a stake that so supersede my initial realistic goal.

So, if tomorrows, hopefully positive cash balance, announcement does not change the share price then what can?

Well, hopefully an announcement of grants obtained to research CBR’s ability to fight Ebola and HIV.

(If I was to prioritize, it would be Ebola. Imagine Ebola getting out of control like Covid-19, the difference is that Ebola has a death rate around 50%)

But the reality is most likely, that there is much more funding for research into HIV.

A quick google search “foundations funding hiv research” will likely give you the following suggestions:

AmfAR
Elton John Foundation
Gates Foundation
APA.org
And many more

I know Hemogenyx is not Nonprofit, but the question is if amfAR will make an exception with Hemogenyx and our ground breaking CBR.

“You can submit queries at any time. Full proposals will be reviewed each February, May and August, with funding to start in March, June and September.”

https://www.amfar.org/research/target-grants/

Going through the Elton John AIDS Foundation website, it does not appear obvious to me that they fund medical research. But the word BESPOKE in the following sentence gives me hope that an exception could be made for Hemogenyx.

“As a grant-making organisation, we create bespoke partnerships and announce opportunities for funding while carefully monitoring and evaluating the impact of all projects with our grantees.”

I mean, it would be quite something for Sir Elton and his foundation to say that they have helped fund the cure of AIDS.

https://www.eltonjohnaidsfoundation.org/what-we-do/what-we-fund/

Unfortunately, I doubt that we will see the share price spike, based on our remaining cash balance.

But I would love to be proved wrong.

I keep pulling my hair out, thinking of reasons why our share price is as low as it is.
Especially after the CBR news last month.

And the best explanation that I can come up with, is that there simply is no appetite for the risk, that there is in this share at the moment.

And for that reason, in my most pessimistic moment, I am preparing myself mentally, for no serious rerate until positive clinical trials.

The reasoning for this pessimistic view, is that everyone that HOPE, BELIEVES etc etc in the science would buy like crazy at these levels. (as much as their situation allows) even if there was a risk of further dilution.

Whatever the sum, announced this week, will be, will it be enough to convince the more sophisticated risk adversed investors to board this train?

Or does it take the announcement of positive clinical trials for that to happen?
Or will entering clinical trials be enough to act as a catalyst?

We will find out soon enough what it takes, maybe this week or the next ( Bank holiday coming up) or maybe in the next couple of months.

Here's to hoping for the immediate future.

Just stumbled upon this article by coincidence, but thought it would be worth sharing.

"Why experts are terrified of a human-made pandemic — and what we can do to stop it"

https://www.vox.com/22937531/virus-lab-safety-pandemic-prevention

Clearly the author have not heard about CBR and Hemogenyx.

If CBR can deliver against all or just really many different kind of virus, then this article shows one of the reasons why CBR is going to be huge.

Well worth a read over the holidays.

@HereForHemo.
Exactly, well said. I rest my case.

I'd only like to add that we got the humanized mice and that might be almost as good as the real thing. And that HEMOGENYX have been in collaboration with some pretty big names for years.

That is why I am so confident in this company and can be patient and see this as another day where I could have bought more shares at a fantastic price (if I had the funds)

Patience is all that is needed (and positive results obviously)

So, if I am correct in my assumptions that the most sensible investors will wait buying into Hemogenyx until we get positive results, then we can only rely on those with a more gambling side to invest at this stage.

Ask yourself :
How likely is someone with a gambling side to invest in this share based on the negative conversation on this board about the low share price and questions about can we trust our CEO.

If you have no trust in our CEO, you better GO.